On the one hand, MT2A is a pro-oncogene in breast cancer 27, prostate cancer 28, large B cell lymphoma 29, and adrenocortical cancer 30, and closely related with unfavorable prognosis of numerous malignant tumors. This evidence concerns the gene MT2A and prostate carcinoma.